Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 40 | 2022 | 1856 | 5.720 |
Why?
|
Retroperitoneal Neoplasms | 17 | 2022 | 339 | 5.360 |
Why?
|
Extremities | 14 | 2020 | 867 | 2.570 |
Why?
|
Liposarcoma | 6 | 2022 | 310 | 1.820 |
Why?
|
Mesothelioma | 12 | 2015 | 813 | 1.770 |
Why?
|
Pleural Neoplasms | 11 | 2015 | 619 | 1.700 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 36 | 2021 | 4853 | 1.520 |
Why?
|
Neoplasm Recurrence, Local | 28 | 2022 | 8864 | 1.410 |
Why?
|
Lung Neoplasms | 48 | 2021 | 12446 | 1.410 |
Why?
|
Soft Tissue Neoplasms | 9 | 2022 | 1327 | 1.330 |
Why?
|
Radiotherapy, Adjuvant | 21 | 2021 | 1832 | 1.310 |
Why?
|
Tumor Burden | 10 | 2020 | 1932 | 1.220 |
Why?
|
Organs at Risk | 3 | 2015 | 330 | 1.080 |
Why?
|
Pneumonectomy | 12 | 2018 | 1071 | 1.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 38 | 2021 | 11269 | 0.990 |
Why?
|
Radiation Oncology | 4 | 2021 | 504 | 0.980 |
Why?
|
Hemangiosarcoma | 4 | 2020 | 223 | 0.920 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 4 | 2021 | 1549 | 0.730 |
Why?
|
Radiotherapy Dosage | 13 | 2021 | 2903 | 0.720 |
Why?
|
Preoperative Care | 5 | 2021 | 2368 | 0.650 |
Why?
|
Radiation Pneumonitis | 4 | 2017 | 98 | 0.640 |
Why?
|
Radiotherapy, Intensity-Modulated | 6 | 2017 | 779 | 0.630 |
Why?
|
Neoplasm, Residual | 4 | 2017 | 1001 | 0.620 |
Why?
|
Combined Modality Therapy | 26 | 2022 | 8941 | 0.620 |
Why?
|
Survival Rate | 36 | 2020 | 13363 | 0.600 |
Why?
|
Radiotherapy | 6 | 2021 | 1627 | 0.590 |
Why?
|
Neoadjuvant Therapy | 9 | 2021 | 2603 | 0.590 |
Why?
|
Cerebellar Neoplasms | 1 | 2019 | 598 | 0.520 |
Why?
|
Medulloblastoma | 1 | 2019 | 715 | 0.500 |
Why?
|
Fibrosarcoma | 2 | 2017 | 345 | 0.490 |
Why?
|
Disease-Free Survival | 18 | 2020 | 7078 | 0.480 |
Why?
|
Vinblastine | 11 | 2013 | 508 | 0.480 |
Why?
|
Genital Neoplasms, Male | 1 | 2013 | 75 | 0.480 |
Why?
|
Models, Economic | 1 | 2017 | 725 | 0.470 |
Why?
|
Thyroglobulin | 1 | 2012 | 119 | 0.460 |
Why?
|
Neoplasm Staging | 36 | 2021 | 11244 | 0.460 |
Why?
|
Brachytherapy | 3 | 2014 | 1284 | 0.440 |
Why?
|
Aged | 90 | 2021 | 162592 | 0.410 |
Why?
|
Middle Aged | 103 | 2021 | 215428 | 0.410 |
Why?
|
Radiosurgery | 5 | 2018 | 1347 | 0.390 |
Why?
|
Aged, 80 and over | 42 | 2020 | 58752 | 0.390 |
Why?
|
Prognosis | 30 | 2021 | 29148 | 0.380 |
Why?
|
Epirubicin | 11 | 2006 | 83 | 0.380 |
Why?
|
Solitary Fibrous Tumors | 2 | 2020 | 73 | 0.380 |
Why?
|
Upper Extremity | 2 | 2012 | 547 | 0.380 |
Why?
|
Humans | 152 | 2022 | 709431 | 0.370 |
Why?
|
Adult | 87 | 2022 | 212298 | 0.360 |
Why?
|
Carcinoma, Small Cell | 4 | 2006 | 432 | 0.360 |
Why?
|
Chemotherapy, Adjuvant | 14 | 2018 | 3535 | 0.360 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 631 | 0.350 |
Why?
|
Lymph Nodes | 2 | 2020 | 3431 | 0.350 |
Why?
|
Carcinoma, Papillary | 2 | 2015 | 804 | 0.340 |
Why?
|
Neck | 1 | 2012 | 697 | 0.340 |
Why?
|
Kaplan-Meier Estimate | 10 | 2019 | 6830 | 0.330 |
Why?
|
Gastrointestinal Diseases | 2 | 2015 | 1155 | 0.330 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1063 | 0.320 |
Why?
|
Peritoneal Cavity | 2 | 2015 | 156 | 0.320 |
Why?
|
Breast Neoplasms | 22 | 2021 | 19798 | 0.320 |
Why?
|
Female | 111 | 2021 | 377269 | 0.310 |
Why?
|
Cisplatin | 16 | 2013 | 1663 | 0.310 |
Why?
|
Ifosfamide | 9 | 2013 | 225 | 0.290 |
Why?
|
Rare Diseases | 1 | 2010 | 511 | 0.290 |
Why?
|
Follow-Up Studies | 28 | 2020 | 39394 | 0.280 |
Why?
|
Thyroid Neoplasms | 3 | 2015 | 2214 | 0.280 |
Why?
|
Treatment Outcome | 36 | 2021 | 61963 | 0.280 |
Why?
|
Male | 86 | 2021 | 351848 | 0.280 |
Why?
|
Radiation Dosage | 7 | 2021 | 2044 | 0.270 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 397 | 0.270 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5233 | 0.260 |
Why?
|
Retrospective Studies | 45 | 2022 | 71151 | 0.250 |
Why?
|
Survival Analysis | 18 | 2017 | 10603 | 0.240 |
Why?
|
Deoxycytidine | 4 | 2013 | 841 | 0.240 |
Why?
|
Skin Neoplasms | 2 | 2020 | 5349 | 0.240 |
Why?
|
Treatment Failure | 6 | 2015 | 2683 | 0.240 |
Why?
|
Consensus | 5 | 2022 | 2668 | 0.230 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2020 | 363 | 0.230 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2019 | 569 | 0.220 |
Why?
|
Postoperative Complications | 6 | 2020 | 15035 | 0.220 |
Why?
|
Leiomyosarcoma | 3 | 2019 | 457 | 0.210 |
Why?
|
Bone Neoplasms | 4 | 2016 | 2568 | 0.210 |
Why?
|
Liposarcoma, Myxoid | 1 | 2021 | 64 | 0.210 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2021 | 54 | 0.210 |
Why?
|
Not-For-Profit Insurance Plans | 1 | 2020 | 2 | 0.200 |
Why?
|
United States Department of Defense | 1 | 2020 | 30 | 0.200 |
Why?
|
Observer Variation | 3 | 2016 | 2696 | 0.200 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 7497 | 0.200 |
Why?
|
Hemangiopericytoma | 1 | 2020 | 78 | 0.200 |
Why?
|
Postoperative Care | 2 | 2019 | 1513 | 0.200 |
Why?
|
Neuroectodermal Tumors | 1 | 1999 | 25 | 0.190 |
Why?
|
Amputation | 2 | 2017 | 800 | 0.180 |
Why?
|
Paclitaxel | 8 | 2021 | 1631 | 0.180 |
Why?
|
Liver Transplantation | 6 | 1999 | 2018 | 0.180 |
Why?
|
Fibromatosis, Aggressive | 2 | 2016 | 114 | 0.180 |
Why?
|
Diethylstilbestrol | 2 | 1997 | 85 | 0.170 |
Why?
|
Heart Diseases | 3 | 2021 | 2751 | 0.170 |
Why?
|
Collagen Diseases | 1 | 2017 | 36 | 0.170 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2011 | 445 | 0.170 |
Why?
|
Colon | 2 | 2017 | 1772 | 0.170 |
Why?
|
Floxuridine | 1 | 1996 | 52 | 0.160 |
Why?
|
Young Adult | 11 | 2020 | 56163 | 0.160 |
Why?
|
Scalp | 1 | 2020 | 375 | 0.160 |
Why?
|
Predictive Value of Tests | 10 | 2016 | 15316 | 0.150 |
Why?
|
Analysis of Variance | 5 | 2020 | 6563 | 0.150 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 1997 | 638 | 0.150 |
Why?
|
Thyroidectomy | 2 | 2012 | 887 | 0.150 |
Why?
|
Neoplasm Metastasis | 11 | 2019 | 5168 | 0.150 |
Why?
|
Infarction | 1 | 2017 | 218 | 0.150 |
Why?
|
Hepatectomy | 2 | 2015 | 582 | 0.140 |
Why?
|
Sumoylation | 1 | 2015 | 86 | 0.140 |
Why?
|
Adrenal Glands | 1 | 2017 | 543 | 0.140 |
Why?
|
Receptors, Progesterone | 2 | 2019 | 1115 | 0.140 |
Why?
|
Proportional Hazards Models | 6 | 2017 | 12442 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 7 | 2016 | 20307 | 0.130 |
Why?
|
Salvage Therapy | 2 | 2018 | 1298 | 0.130 |
Why?
|
Cyclophosphamide | 10 | 2003 | 2195 | 0.130 |
Why?
|
Risk Factors | 17 | 2019 | 70264 | 0.130 |
Why?
|
Astrocytoma | 1 | 2018 | 792 | 0.130 |
Why?
|
Fluorouracil | 8 | 2003 | 1641 | 0.130 |
Why?
|
Fractures, Spontaneous | 1 | 2016 | 241 | 0.130 |
Why?
|
Lower Extremity | 2 | 2012 | 1038 | 0.130 |
Why?
|
Biological Products | 1 | 2022 | 847 | 0.120 |
Why?
|
Nephrectomy | 2 | 2017 | 996 | 0.120 |
Why?
|
Drainage | 1 | 1999 | 1135 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2003 | 1528 | 0.120 |
Why?
|
Thoracic Surgical Procedures | 2 | 2013 | 335 | 0.120 |
Why?
|
Lymphatic Metastasis | 5 | 2017 | 2992 | 0.120 |
Why?
|
Necrosis | 1 | 2017 | 1632 | 0.120 |
Why?
|
Drug Administration Schedule | 7 | 2007 | 5112 | 0.120 |
Why?
|
Coronary Vessels | 2 | 2021 | 2941 | 0.120 |
Why?
|
Lymph Node Excision | 2 | 2012 | 1182 | 0.120 |
Why?
|
Limb Salvage | 2 | 2015 | 444 | 0.120 |
Why?
|
Thoracic Wall | 1 | 2014 | 193 | 0.110 |
Why?
|
Receptors, Estrogen | 3 | 2019 | 2137 | 0.110 |
Why?
|
Duodenum | 1 | 2015 | 479 | 0.110 |
Why?
|
Asbestos | 1 | 2013 | 243 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2019 | 8733 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 34096 | 0.110 |
Why?
|
Radiation Injuries | 1 | 2019 | 1231 | 0.110 |
Why?
|
Carcinogens | 1 | 2013 | 460 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2020 | 1213 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1594 | 0.100 |
Why?
|
Heart | 3 | 2021 | 4281 | 0.100 |
Why?
|
Myoglobin | 1 | 2011 | 158 | 0.100 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1042 | 0.100 |
Why?
|
Stomach | 1 | 2015 | 683 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 5 | 1997 | 629 | 0.100 |
Why?
|
Skull Neoplasms | 1 | 2011 | 177 | 0.100 |
Why?
|
Tamoxifen | 2 | 2007 | 991 | 0.100 |
Why?
|
Neoplasms, Second Primary | 2 | 2012 | 1010 | 0.100 |
Why?
|
Brain Neoplasms | 5 | 2018 | 8756 | 0.100 |
Why?
|
Creatine Kinase, MB Form | 1 | 2011 | 220 | 0.100 |
Why?
|
Fibrosis | 1 | 2017 | 1922 | 0.100 |
Why?
|
Endonucleases | 1 | 2013 | 390 | 0.100 |
Why?
|
Hyperthermia, Induced | 1 | 2013 | 362 | 0.100 |
Why?
|
Connective Tissue | 2 | 2022 | 385 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2003 | 900 | 0.100 |
Why?
|
Time Factors | 11 | 2017 | 41295 | 0.090 |
Why?
|
Radiography | 3 | 2015 | 6993 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2285 | 0.090 |
Why?
|
Dura Mater | 1 | 2011 | 295 | 0.090 |
Why?
|
Chest Pain | 2 | 2014 | 1091 | 0.090 |
Why?
|
Vascular Diseases | 1 | 2017 | 1152 | 0.090 |
Why?
|
Confidence Intervals | 3 | 2007 | 3000 | 0.090 |
Why?
|
Edema | 1 | 2013 | 744 | 0.090 |
Why?
|
Incidence | 10 | 2021 | 20587 | 0.090 |
Why?
|
ras Proteins | 1 | 2014 | 1122 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2013 | 803 | 0.090 |
Why?
|
Adolescent | 12 | 2017 | 85327 | 0.090 |
Why?
|
Intestine, Small | 1 | 2015 | 1235 | 0.090 |
Why?
|
Population Surveillance | 1 | 2019 | 2642 | 0.090 |
Why?
|
Neutropenia | 6 | 1998 | 868 | 0.090 |
Why?
|
Heart Neoplasms | 1 | 2012 | 387 | 0.090 |
Why?
|
Digestive System Surgical Procedures | 1 | 2013 | 567 | 0.090 |
Why?
|
Algorithms | 4 | 2015 | 13668 | 0.080 |
Why?
|
Women's Health | 1 | 1997 | 1915 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8053 | 0.080 |
Why?
|
Disease Progression | 5 | 2020 | 13298 | 0.080 |
Why?
|
Methotrexate | 6 | 2003 | 1710 | 0.080 |
Why?
|
Smoking | 4 | 2013 | 8940 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2007 | 11384 | 0.080 |
Why?
|
Antineoplastic Agents | 6 | 2013 | 13763 | 0.080 |
Why?
|
Etoposide | 3 | 2006 | 632 | 0.080 |
Why?
|
Skin Transplantation | 1 | 2012 | 1128 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2013 | 1032 | 0.080 |
Why?
|
Injections, Intravenous | 3 | 2006 | 1482 | 0.080 |
Why?
|
Troponin I | 1 | 2011 | 627 | 0.080 |
Why?
|
Cell Survival | 1 | 2017 | 6184 | 0.070 |
Why?
|
Neoplasm Proteins | 2 | 2015 | 3884 | 0.070 |
Why?
|
Cohort Studies | 7 | 2021 | 39650 | 0.070 |
Why?
|
Radiation Tolerance | 1 | 2009 | 514 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3085 | 0.070 |
Why?
|
Rhabdomyosarcoma | 2 | 2016 | 381 | 0.070 |
Why?
|
Carcinoma | 2 | 2015 | 2330 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1384 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 2927 | 0.070 |
Why?
|
Diagnostic Imaging | 2 | 2021 | 3496 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 183 | 0.070 |
Why?
|
Radiotherapy, Conformal | 2 | 2020 | 559 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1443 | 0.070 |
Why?
|
Methylprednisolone | 3 | 1999 | 401 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 2842 | 0.070 |
Why?
|
Diabetes Complications | 1 | 2012 | 1403 | 0.070 |
Why?
|
Guanine | 1 | 2006 | 282 | 0.070 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2008 | 274 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4696 | 0.070 |
Why?
|
Glutamates | 1 | 2006 | 407 | 0.070 |
Why?
|
Acute Disease | 1 | 2015 | 7201 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2016 | 14895 | 0.070 |
Why?
|
Aortic Aneurysm | 1 | 2010 | 680 | 0.070 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3740 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2020 | 2987 | 0.070 |
Why?
|
Boston | 2 | 2015 | 9409 | 0.070 |
Why?
|
Aneurysm, Dissecting | 1 | 2010 | 653 | 0.070 |
Why?
|
Immunotherapy | 1 | 2020 | 4114 | 0.060 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 446 | 0.060 |
Why?
|
Heart Failure | 3 | 2021 | 9901 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 1521 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 1473 | 0.060 |
Why?
|
Surgical Flaps | 1 | 2012 | 1627 | 0.060 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 916 | 0.060 |
Why?
|
Decision Making | 1 | 2017 | 3807 | 0.060 |
Why?
|
Prospective Studies | 8 | 2022 | 50734 | 0.060 |
Why?
|
Patient Care Team | 1 | 2015 | 2596 | 0.060 |
Why?
|
Filgrastim | 3 | 1997 | 135 | 0.060 |
Why?
|
Infusions, Intravenous | 2 | 2006 | 2314 | 0.060 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2007 | 654 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2011 | 1544 | 0.060 |
Why?
|
Point-of-Care Systems | 1 | 2011 | 1104 | 0.060 |
Why?
|
Kidney | 1 | 2017 | 6872 | 0.060 |
Why?
|
Medical Oncology | 2 | 2021 | 2070 | 0.060 |
Why?
|
Palliative Care | 2 | 2009 | 3274 | 0.050 |
Why?
|
Wound Healing | 1 | 2012 | 2792 | 0.050 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2694 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 4 | 1997 | 681 | 0.050 |
Why?
|
Propensity Score | 2 | 2020 | 1739 | 0.050 |
Why?
|
Solitary Fibrous Tumor, Pleural | 1 | 2020 | 26 | 0.050 |
Why?
|
Mitomycin | 2 | 1998 | 248 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2379 | 0.050 |
Why?
|
Mitotic Index | 1 | 2020 | 175 | 0.050 |
Why?
|
Age Factors | 5 | 2020 | 18954 | 0.050 |
Why?
|
Mastectomy | 2 | 2012 | 1671 | 0.050 |
Why?
|
Furans | 1 | 2021 | 195 | 0.050 |
Why?
|
Ketones | 1 | 2021 | 182 | 0.050 |
Why?
|
Retreatment | 1 | 2021 | 629 | 0.050 |
Why?
|
Drug Interactions | 1 | 2004 | 1462 | 0.050 |
Why?
|
Hemoperitoneum | 1 | 1999 | 39 | 0.050 |
Why?
|
Child | 4 | 2021 | 73998 | 0.050 |
Why?
|
Biliary Fistula | 1 | 1999 | 37 | 0.050 |
Why?
|
Vindesine | 1 | 1998 | 12 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2021 | 352 | 0.050 |
Why?
|
Skin | 1 | 2012 | 4319 | 0.040 |
Why?
|
Vincristine | 3 | 1997 | 1041 | 0.040 |
Why?
|
Evaluation Studies as Topic | 3 | 2016 | 1753 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8019 | 0.040 |
Why?
|
Leucovorin | 2 | 1997 | 613 | 0.040 |
Why?
|
Genes, bcl-2 | 1 | 1998 | 119 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6317 | 0.040 |
Why?
|
Radiotherapy, High-Energy | 1 | 1999 | 244 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2012 | 1087 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6123 | 0.040 |
Why?
|
Doxorubicin | 5 | 1997 | 2238 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2539 | 0.040 |
Why?
|
Karnofsky Performance Status | 1 | 1998 | 190 | 0.040 |
Why?
|
Respiratory Insufficiency | 1 | 2006 | 1142 | 0.040 |
Why?
|
Drug Tolerance | 2 | 1996 | 406 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 2202 | 0.040 |
Why?
|
Carboplatin | 2 | 1998 | 798 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17347 | 0.040 |
Why?
|
North America | 1 | 2020 | 1197 | 0.040 |
Why?
|
Cyclin D1 | 1 | 1999 | 490 | 0.040 |
Why?
|
Azathioprine | 1 | 1998 | 347 | 0.040 |
Why?
|
Isomerism | 1 | 1996 | 213 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 1999 | 827 | 0.040 |
Why?
|
Angina Pectoris | 1 | 2021 | 1007 | 0.040 |
Why?
|
Death | 1 | 2021 | 557 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 843 | 0.040 |
Why?
|
Remission Induction | 3 | 1996 | 2414 | 0.040 |
Why?
|
Peritonitis | 1 | 1999 | 380 | 0.040 |
Why?
|
Recombinant Proteins | 6 | 1997 | 6946 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2017 | 12517 | 0.040 |
Why?
|
Estrogens, Non-Steroidal | 1 | 1996 | 46 | 0.040 |
Why?
|
Critical Pathways | 1 | 2020 | 457 | 0.040 |
Why?
|
Child, Preschool | 1 | 2019 | 41195 | 0.040 |
Why?
|
Hernia, Inguinal | 1 | 1998 | 191 | 0.040 |
Why?
|
Thymidine | 1 | 1996 | 355 | 0.040 |
Why?
|
Immunohistochemistry | 4 | 2019 | 11904 | 0.040 |
Why?
|
Adrenalectomy | 1 | 2017 | 307 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 1996 | 638 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9802 | 0.030 |
Why?
|
Abdominal Neoplasms | 1 | 1997 | 299 | 0.030 |
Why?
|
Leukocyte Count | 2 | 1997 | 1677 | 0.030 |
Why?
|
Thoracic Neoplasms | 1 | 1997 | 260 | 0.030 |
Why?
|
Administration, Oral | 2 | 2007 | 3952 | 0.030 |
Why?
|
Anthracyclines | 1 | 1996 | 253 | 0.030 |
Why?
|
Sarcoma, Synovial | 1 | 1996 | 167 | 0.030 |
Why?
|
Tacrolimus | 1 | 1998 | 716 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2137 | 0.030 |
Why?
|
Immunization, Passive | 1 | 1997 | 638 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2013 | 60 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 1340 | 0.030 |
Why?
|
Receptor, IGF Type 1 | 1 | 1996 | 398 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2019 | 505 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3365 | 0.030 |
Why?
|
Length of Stay | 2 | 2020 | 6273 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2004 | 2015 | 0.030 |
Why?
|
Morbidity | 1 | 1999 | 1694 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 1998 | 1667 | 0.030 |
Why?
|
Rib Fractures | 1 | 2014 | 106 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2019 | 891 | 0.030 |
Why?
|
Esophagitis | 1 | 2013 | 140 | 0.030 |
Why?
|
Feasibility Studies | 3 | 1996 | 4903 | 0.030 |
Why?
|
Colectomy | 1 | 2017 | 653 | 0.030 |
Why?
|
Mutation | 2 | 2014 | 29242 | 0.030 |
Why?
|
Hepatitis B | 1 | 1997 | 643 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7801 | 0.030 |
Why?
|
Prevalence | 2 | 2019 | 14849 | 0.030 |
Why?
|
Focus Groups | 1 | 2016 | 1228 | 0.030 |
Why?
|
Radioisotopes | 1 | 2013 | 513 | 0.030 |
Why?
|
United States | 4 | 2020 | 67177 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 7410 | 0.030 |
Why?
|
Biopsy | 2 | 2021 | 6786 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 3946 | 0.030 |
Why?
|
Mitosis | 1 | 1996 | 1245 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3599 | 0.030 |
Why?
|
Neck Dissection | 1 | 2012 | 214 | 0.020 |
Why?
|
Home Care Services | 1 | 1996 | 593 | 0.020 |
Why?
|
Asthenia | 1 | 1969 | 18 | 0.020 |
Why?
|
Quality of Life | 2 | 2021 | 11553 | 0.020 |
Why?
|
Lorazepam | 1 | 1990 | 145 | 0.020 |
Why?
|
Liver Cirrhosis | 2 | 1997 | 1723 | 0.020 |
Why?
|
Adjustment Disorders | 1 | 1969 | 72 | 0.020 |
Why?
|
Lymphoma | 1 | 2019 | 1908 | 0.020 |
Why?
|
Pyridoxine | 1 | 1969 | 105 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1848 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 128 | 0.020 |
Why?
|
Lung | 3 | 2017 | 9617 | 0.020 |
Why?
|
Safety | 1 | 2014 | 1223 | 0.020 |
Why?
|
Lung Diseases | 2 | 1998 | 1890 | 0.020 |
Why?
|
Perioperative Care | 1 | 2017 | 1067 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2006 | 5392 | 0.020 |
Why?
|
Diarrhea | 1 | 1996 | 1393 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 731 | 0.020 |
Why?
|
Radiometry | 1 | 2014 | 810 | 0.020 |
Why?
|
Survival | 1 | 2008 | 162 | 0.020 |
Why?
|
Virus Replication | 1 | 1997 | 2532 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2012 | 321 | 0.020 |
Why?
|
Gadolinium | 1 | 2013 | 907 | 0.020 |
Why?
|
Immunosuppressive Agents | 2 | 1999 | 4228 | 0.020 |
Why?
|
Reoperation | 2 | 2013 | 4155 | 0.020 |
Why?
|
Pilot Projects | 3 | 2016 | 8036 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 631 | 0.020 |
Why?
|
Keratin-7 | 1 | 2007 | 47 | 0.020 |
Why?
|
Keratin-19 | 1 | 2007 | 33 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2794 | 0.020 |
Why?
|
Antifibrinolytic Agents | 1 | 2010 | 246 | 0.020 |
Why?
|
Vomiting | 1 | 1990 | 635 | 0.020 |
Why?
|
Porphyrins | 1 | 1969 | 363 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2891 | 0.020 |
Why?
|
Computer Simulation | 1 | 2001 | 6059 | 0.020 |
Why?
|
Sex Characteristics | 1 | 1997 | 2497 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1665 | 0.020 |
Why?
|
Interleukin-2 | 1 | 1994 | 2013 | 0.020 |
Why?
|
Laparoscopy | 1 | 1998 | 1990 | 0.020 |
Why?
|
Bone Marrow | 1 | 1997 | 2939 | 0.020 |
Why?
|
Interferon-alpha | 1 | 1991 | 912 | 0.020 |
Why?
|
Vitamin B 12 | 1 | 1969 | 508 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 1969 | 487 | 0.020 |
Why?
|
Hepatitis C, Chronic | 1 | 1994 | 1003 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4325 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 902 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1997 | 2075 | 0.020 |
Why?
|
Liver Neoplasms | 2 | 1997 | 4092 | 0.020 |
Why?
|
Hypotension | 1 | 1969 | 820 | 0.020 |
Why?
|
African Americans | 1 | 2020 | 5194 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2014 | 16161 | 0.020 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2010 | 615 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 8971 | 0.020 |
Why?
|
Premenopause | 1 | 2007 | 1018 | 0.020 |
Why?
|
DNA Repair | 1 | 2013 | 2032 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 9504 | 0.010 |
Why?
|
Ultrasonography | 1 | 2016 | 5913 | 0.010 |
Why?
|
Mastectomy, Segmental | 1 | 2007 | 922 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2494 | 0.010 |
Why?
|
Leukemia | 1 | 1969 | 1504 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2014 | 4020 | 0.010 |
Why?
|
Cell Division | 2 | 1999 | 4787 | 0.010 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2010 | 1153 | 0.010 |
Why?
|
Drug Therapy, Combination | 3 | 1998 | 6583 | 0.010 |
Why?
|
Risk Assessment | 2 | 2016 | 23519 | 0.010 |
Why?
|
Recurrence | 3 | 1998 | 8279 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 13362 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1969 | 1850 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11304 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12955 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 21874 | 0.010 |
Why?
|
Ploidies | 1 | 1999 | 280 | 0.010 |
Why?
|
Postmenopause | 1 | 2007 | 2406 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19470 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9813 | 0.010 |
Why?
|
Quality Control | 1 | 2001 | 876 | 0.010 |
Why?
|
Cause of Death | 2 | 1999 | 3563 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 385 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2001 | 2443 | 0.010 |
Why?
|
Least-Squares Analysis | 1 | 1997 | 387 | 0.010 |
Why?
|
Antidotes | 1 | 1997 | 137 | 0.010 |
Why?
|
SEER Program | 1 | 2002 | 1556 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 10551 | 0.010 |
Why?
|
Tritium | 1 | 1996 | 817 | 0.010 |
Why?
|
Hepatitis B Surface Antigens | 1 | 1997 | 288 | 0.010 |
Why?
|
Mitomycins | 1 | 1995 | 55 | 0.010 |
Why?
|
Thoracotomy | 1 | 1997 | 364 | 0.010 |
Why?
|
Graft Rejection | 2 | 1999 | 4409 | 0.010 |
Why?
|
Thorax | 1 | 1997 | 506 | 0.010 |
Why?
|
Stroke Volume | 2 | 1997 | 4452 | 0.010 |
Why?
|
Hepatitis C Antibodies | 1 | 1994 | 140 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2000 | 1818 | 0.010 |
Why?
|
Hepatitis B virus | 1 | 1997 | 450 | 0.010 |
Why?
|
Immunoglobulins | 1 | 1997 | 927 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15548 | 0.010 |
Why?
|
Mucous Membrane | 1 | 1996 | 679 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2001 | 2397 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1996 | 660 | 0.010 |
Why?
|
Survivors | 1 | 2002 | 2141 | 0.010 |
Why?
|
Interferons | 1 | 1995 | 680 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1996 | 687 | 0.010 |
Why?
|
DNA, Viral | 1 | 1997 | 2302 | 0.010 |
Why?
|
Leukopenia | 1 | 1990 | 213 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1991 | 674 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 1990 | 563 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1996 | 1406 | 0.010 |
Why?
|
Fever | 1 | 1996 | 1588 | 0.010 |
Why?
|
Biliary Tract Diseases | 1 | 1969 | 160 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1999 | 6185 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1991 | 447 | 0.010 |
Why?
|
Graft Survival | 1 | 1998 | 3758 | 0.010 |
Why?
|
Platelet Count | 1 | 1990 | 799 | 0.000 |
Why?
|
Urologic Diseases | 1 | 1969 | 250 | 0.000 |
Why?
|
Embolization, Therapeutic | 1 | 1997 | 1416 | 0.000 |
Why?
|
Drug Synergism | 1 | 1991 | 1890 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 4012 | 0.000 |
Why?
|
Surgical Procedures, Operative | 1 | 1998 | 1884 | 0.000 |
Why?
|
Antibodies | 1 | 1994 | 2472 | 0.000 |
Why?
|
RNA, Viral | 1 | 1994 | 2845 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4727 | 0.000 |
Why?
|
Ventricular Function, Left | 1 | 1996 | 3357 | 0.000 |
Why?
|
Melanoma | 1 | 2002 | 5503 | 0.000 |
Why?
|
Pain | 1 | 1998 | 4623 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2002 | 6564 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1994 | 4500 | 0.000 |
Why?
|
Apoptosis | 1 | 1998 | 10133 | 0.000 |
Why?
|
Drug Resistance, Neoplasm | 1 | 1996 | 5227 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1990 | 12008 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1991 | 6462 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1990 | 9857 | 0.000 |
Why?
|